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There is an urgent need to make drug discovery cheaper and faster. This will
enable the development of treatments for diseases currently neglected for
economic reasons, such as tropical and orphan diseases, and generally increase
the supply of new drugs. Here, we report the Robot Scientist ‘Eve’ designed to
make drug discovery more economical. A Robot Scientist is a laboratory auto-
mation system that uses artificial intelligence (AI) techniques to discover
scientific knowledge through cycles of experimentation. Eve integrates and
automates library-screening, hit-confirmation, and lead generation through
cycles of quantitative structure activity relationship learning and testing.
Using econometric modelling we demonstrate that the use of AI to select
compounds economically outperforms standard drug screening. For further
efficiency Eve uses a standardized form of assay to compute Boolean functions
of compound properties. These assays can be quickly and cheaply engineered
using synthetic biology, enabling more targets to be assayed for a given
budget. Eve has repositioned several drugs against specific targets in parasites
that cause tropical diseases. One validated discovery is that the anti-cancer
compound TNP-470 is a potent inhibitor of dihydrofolate reductase from the
malaria-causing parasite Plasmodium vivax.1. Introduction
New drugs are generally slow (more than 10 years) and expensive (more than $1
Billion) to discover and develop. Consequently tropical diseases, malaria, schisto-
somiasis, Chagas’ disease, etc., which kill millions of people and infect hundreds
of millions of others are ‘neglected’ [1,2]; and ‘orphan’ diseases with few sufferers
remain untreatable [3]. More generally, the pharmaceutical industry is struggling
to cope with spiralling drug discovery and development costs [4].
The most important steps in early stage drug design are shown in figure 1 [5].
A key initial step is to develop an ‘assay’. This is a ‘wet’ (biological/chemical) or
‘dry’ (computational) experiment that estimates whether a small molecule (com-
pound) is likely to treat a disease. This assay should be relatively cheap and fast to
execute as it will be run multiple times. A compound that passes the assay is
called a ‘hit’. The next step is to run a drug screen, where a ‘library’ (set) of
standardized synthetic
biology assays robot scientist
assay
design
library
screen
hit
confirmation
learn and test
QSAR leadcompound
Figure 1. Early stage drug design. The contribution of standardized synthetic biology assays and Eve to a cheaper faster drug discovery pipeline. (Online version
in colour.)
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large, tens/hundreds of thousands, maybe millions of com-
pounds. Such mass screening is generally done in a brute-
force and unintelligent way: ‘begin at the beginning and go
on till you come to the end: then stop’ (Lewis Carroll). As the
a priori probability of any library compound being a hit is
low, it is difficult to design an assay that does not have an
appreciable number of false positive hits. Therefore, it is gener-
ally necessary to execute experiments to retest (‘confirm’) the
hits. These experiments are more expensive and slow to exe-
cute, but have a much lower false positive probability. From
the set of confirmed hit activities, a quantitative structure
activity relationship (QSAR) is learnt [6]. This is a function
whose input is the structure of a compound, and whose
output is the predicted activity on the assay. As the output is
typically a real number, QSAR learning is generally a
regression task. QSARs generalize the results of assays and
guide the synthesis of new compounds. After new compounds
are synthesized, they are tested against the hit-confirmation
assay, and the results of these assays are used to learn a more
accurate QSAR, and the cycle repeated. The process is termi-
nated when a compound is found that has a sufficiently
high score on the assay, and which passes other tests such as
low predicted toxicity, potential for modification, etc. This
compound is called a ‘lead’.
The standard way to improve the economics of a process
is through automation and standardization [7]. The use of
automation has been enthusiastically pursued by the pharma-
ceutical industry. Much of this effort has gone into making
library screening faster, especially through miniaturization,
with the result that high-throughput robotic systems now rou-
tinely screen millions of compounds in library screens [5]. Less
effort has gone into automating other steps of early stage drug
design, and standardization has been little used.
A natural extension of the trend of increased involvement
of automation in science is the concept of a Robot Scientist
[8,9]. A Robot Scientist automatically: originates hypotheses
to explain observations, devises experiments to test these
hypotheses, physically runs the experiments using laboratory
robotics, interprets the results to change the probability of
hypotheses, and then repeats the cycle. In this way Robot
Scientists can automate high-throughput hypothesis led
research. Robot Scientists are also well suited to recording
scientific knowledge: as the experiments are conceived and
executed automatically by computer, it is possible to comple-
tely capture and digitally curate all aspects of the scientific
process. [9]. The first Robot Scientist ‘Adam’ was designed
to plan and execute yeast microbiological experiments.
Adam was fully automated and during an investigationthere was no essential requirement for a technician, except
to periodically add laboratory consumables and remove
waste. Adam was the first machine demonstrated to have
autonomously discovered novel scientific knowledge [9].
Adam investigated the functional genomics of S. cerevisiae
and discovered the function of locally orphan enzymes—
enzymes known to be in yeast but for which the gene(s)
encoding them are unknown [9]. The advances that distin-
guished Adam from other complex laboratory systems
(such as high-throughput drug-screening pipelines and
X-ray crystallography crystal-screening systems) was its arti-
ficial intelligence (AI) software, its many complex internal
cycles, and its ability to execute high-throughput individually
planned cycles of experiments.
In this paper, we demonstrate the viability of the Robot
Scientist ‘Eve’ in drug discovery. We focus on finding lead
compounds for neglected tropical diseases. However, the
principles and methods used can be generally employed.
The reasons for the focus on neglected tropical diseases are:
— These diseases are a scourge of humanity, infecting hun-
dreds of millions of people, and annually killing
millions of people.
— The aetiology of these diseases is clear, as is what needs to
be done to treat them (kill the parasites), and how to
achieve this treatment with a small molecule drug.
These criteria are not met for many diseases targeted by
the Pharmaceutical Industry.
— There is little competition from the much better funded
Pharmaceutical Industry.
2. Eve
2.1. Design
We report the development of the Robot Scientist Eve
designed to automate early stage drug design (figure 2).
The initial design of Eve was given in [10]. Eve has three inte-
grated modes corresponding to successive stages in lead drug
discovery. In its Library-screening mode, Eve systematically
tests each member from a large set of compounds against
an assay in the standard brute-force way of conventional
mass screening [5]. While simple to automate, brute-force
mass screening is slow and wasteful of resources as every
compound in the library is tested. It is also unintelligent, as
it makes no use of what is learnt during screening. Eve
starts the lead discovery process by mass-screening a subset
of its library to find ‘hit’ compounds for the assay. This
subset is currently chosen randomly.
(b)
(a)
Figure 2. (a) A diagram of Eve. Showing the location of the main instru-
ments. (b) A photo of Eve. Eve has been designed to be flexible in terms
of the biological assays that it can perform, and is physically capable of
screening at a moderately high-throughput rate.
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pounds using multiple repeats and titrations to reduce the
probability of false positives. Eve’s integration of screening
and hit-confirmation is similar to advanced screening sys-
tems that first execute a high-throughput screen, and then a
high-content screen for selected compounds.
Starting from the set of confirmed hits, Eve execu-
tes cycles of statistics/machine learning that hypothesize
QSARs, and tests these QSARs on new compounds. As Eve
currently does not have access to chemical synthesis auto-
mation [11], we applied Eve to screen untested compounds
from its library in lieu of synthesizing compounds. Such intel-
ligent library screening may be more economical than
standard mass screening as it potentially saves on time and
compound use.2.2. Hardware
Eve’s robotic system is capable of moderately high-throughput
compound screening: greater than 10 000 compounds per day,
depending on the length of time taken to assay compounds.
Eve is designed to be sufficiently flexible that it can be rapidly
reconfigured to carry out a number of different biological
assays, using fluorescence, absorbance or cell morphology as
read-outs (figure 2). Eve’s robotic system integrates a range
of off-the-shelf pieces of laboratory automation equipment
into a single system that can perform library-screening, hit-
confirmation and cycles of QSAR hypothesis formation andtesting using selected compounds from a compound library.
Eve can also be reconfigured to copy compound libraries.
Eve’s compound library is maintained in a dry-store, with
the compounds dissolved inDMSO.Compounds to be assayed
are transferred from the storage plates to the assay plates using
a non-contact acoustic transfer liquid-handling system. This
has the advantages of high accuracy and saving pipette tips.
In library-screening mode there is a direct mapping from
storage plates to assay plates, and a single transfer volume is
used in each well. In hit-confirmation and intelligent-screening
modes a single compound from the storage plate is transferred
tomultiplewells in the assay plate, and at different volumes, to
realize multiple repeats dose–response experiments. After the
addition of assay compound, the target yeast strain pool is
added using a simple liquid-handling robot, as the same
volume is added to each well. The yeast pool is created exter-
nally and stored by Eve for use. Once the assay plates are
formed they are placed in a shaking incubator. Every 90 min,
the plates are removed from the incubator, and fluorescence
measured. Eve has twomicroplate readers capable of recording
measurements across a broad range of both excitation and
emission wavelengths. Eve also has an automated microscope
capable of taking both bright-field and fluorescence images
across a broad range of wavelengths. Upon completion of the
assay, the plates are automatically removed from the system.
To transfer the plates between different pieces of laboratory
automation equipment, Eve uses robotic arms and linear
actuators. All plates are bar-coded and movements recorded.
2.3. Low-level software
Software was written to integrate Eve’s AI software with the
robotics and thereby automate and integrate Eve’s early stage
drug design functions: library-screening, hit-confirmation and
QSAR cycles. The software to control the robotics, instrumenta-
tion and used to execute the experiments was written on top of
Peak Analysis and Automation’s Overlord software. An inter-
face was written to a relational database that stores all
experiment-related data and meta-data, e.g. all fluorescence
measurements. The software to parametrize growth curves for
the different yeast strains in each well was taken from the
Adamproject [9]. Themain parameters are estimatedmaximum
growth, doubling time and lag time. These growth parameters
were then transferred to the AI QSAR software. Software was
also written to coordinate library-screening, and to plan hit-
confirmation. This was also integrated with the AI software so
that the active learning algorithmcould select compoundsto test.
2.4. Automated quantitative structure activity
relationship formation
To form QSARs Eve uses least-squares linear regression with
mild 2-norm regularization (ridge regression). This can be
interpreted as a Gaussian process with a linear kernel [12],
hence we can compute the posterior uncertainty, allowing us
to use an optimization method which is more efficient, i.e.
which needs fewer function evaluations [13]. The linear
kernel choice has the distinct advantage that it permits more
efficient computation than other kernels when the dimension-
ality of the feature space is smaller than the number of
examples. The feature space consists of binary fingerprints
of all paths up to length 7. We computed these with Open
Babel [14].
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Figure 3. The form of the standardized assays. From biological knowledge, a specific objective is determined; this is compiled into a propositional logic function,
and synthetic biology is used to engineer a set of yeast strains that compute the function. (Colour, Medical Illustration, Source: National Institute of Allergy and
Infectious Diseases (NIAID), Date Created: 2007, Date Added: 8/20/2013.)
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To select compounds to test its hypotheses Eve uses active
learning [13,15]. The active learning task is comparable to
that in many other areas of science and engineering: identify
or design artefacts that have optimal performance. However,
it has an extra ingredient reminiscent of reinforcement learn-
ing: balancing the exploration of compound space with the
exploitation of regions of highly active compounds. Another
complication is that it is desirable to identify the K best
diverse compounds in the library: ‘leads’ [13]. Therefore,
the QSAR active learning problem is: given a finite pool P
of instances, an unknown QSAR function f that maps
instances x[ P to their target values f(x), an assay (noisy
‘oracle’) that canbequeried for the targetvalueofanyx inbatches
ofN, the numberK of leads required; then find the topK leads in
P. (In computer science, an ‘oracle’ is a machine, theworkings of
which are unexplained,which always returns the correct answer
to a question. A noisy oracle has a probability of returning an
incorrect answer.) We found a successful approach to be a com-
bination of selecting compounds with high estimated activity T,
and high estimated variance, i.e. select the example where
T þ b ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃvar(T)p is maximal [13] (electronic supplementary
material). As it is generally inefficient to assay (or synthesize),
a single compound in a QSAR cycle, batches of N compounds
should be selected (for Eve, N¼ 64). Like the requirement to
find the K best leads this greatly increases the computational
complexity of choosing the best experiment. Therefore, Eve
adopts a greedy strategy to select batch compounds.3. Standardized assays
There are three main forms of assay: computational [16],
biochemical and cell-based [17]. The most general type is com-
putational (in silico screening, [18])—assuming the Church–
Turing thesis [19], they could compute any conceivable assay.The advantages of in silico screening are that it is cheap, fast,
and that compounds can be tested without synthesizing
them. These enable very large libraries to be evaluated, and
hence in silico screening has proved its worth many time [18].
The main disadvantage of in silico screening is that it is compu-
tationally infeasible to simulate the full complexity of biological
systems. Biochemical assays have the advantage of being target-
based (enabling rational drug design), but often assume a
specific mechanism of interaction, and provide little infor-
mation about toxicity, drug uptake into cells and in vivo
activity. Cell-based assays are the most biologically realistic,
but are rarely target-based, and thus provide limited infor-
mation on the mechanism of action of a drug. Moreover,
cell-based assays are not applicable when searching for
compounds active against parasites that are not currently
possible or difficult to culture (e.g. Plasmodium vivax). All
these types of assay are slow and expensive to develop—even
computational ones if reasonable realism is to be achieved.
We have developed a standardized form of screening
assay that combines advantages of computational assays
(generality), biochemical assays (targeted) and using live
cells (biological realism, and early screening for toxicity)
(figure 3). These assays are designed to be automatically
engineered using existing laboratory automation, and can
be generated much faster and more cheaply than the bespoke
assays that are currently standard. This enables more types of
assay to be executed, more efficient use of screening facilities
to be made, and thereby increases the probability of a discov-
ery within a given budget. The assays are biological systems
designed to compute Boolean functions of desired properties
[20]. This concept generalizes previous uses of engineered
cells in drug discovery assays [21–23].
As an illustration, consider the example of designing an
assay that targets both wild-type and pyrimethamine-resistant
(drug-resistant) P. vivax dihydrofolate reductases (DHFRs)
(figure 3). To compute this function, we first engineer a
Table 1. The targets (disease/species/protein/drug-resistant) and libraries screened (May, Maybridge Hitﬁnder; JH, Johns Hopkins University Clinical Compound
Library).
disease species enzyme drug-resistant libraries
malaria P. falciparum DHFR no May, JH
malaria P. falciparum DHFR yes May, JH
malaria P. falciparum DHFR no May, JH
malaria P. vivax DHFR no May, JH
malaria P. vivax DHFR yes May, JH
malaria P. vivax DHFR no May, JH
malaria P. vivax PGK no May, JH
malaria P. vivax NMT no May, JH
Chagas T. cruzi DHFR no May, JH
Chagas T. cruzi PGK no May, JH
Chagas T. cruzi NMT no May, JH
African sleeping sickness T. brucei DHFR no May, JH
African sleeping sickness T. brucei PGK no May, JH
African sleeping sickness T. brucei NMT no May, JH
schistosomiasis S. mansoni DHFR no May, JH
schistosomiasis S. mansoni PGK no May, JH
schistosomiasis S. mansoni NMT no May, JH
leishmaniasis L. major DHFR no May, JH
bacterial infection S. aureus DHFR no May, JH
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coding sequence (cds) replaced by that for wild-type P. vivax
DHFR (yPvDHFRp), then engineer a second chimeric yeast
strain (yPvRdhfrp) with its DHFR cds replaced by that for
drug-resistant P. vivax DHFR. We then engineer a third chi-
meric yeast strain (yHsDHFRp) with its DHFR cds replaced
by that for H. sapiens DHFR. Finally, we apply this biological
system to assay for compounds that inhibit growth of the
strains expressing the parasite targets (yPvDHFRp and
yPvRdhfrp) and not the strain expressing their human counter-
part (yHsDHFRp) [24]. Such compounds are ‘true’ for the
assay. They are unlikely to be cytotoxic, as that would imply
that the yeast strain expressing the human enzyme would
also be inhibited. However, this does not completely remove
the probability of human cytotoxicity as there could be off
target effects specific to human cells, therefore further studies
are required. In practice, Eve grows the strains in competition,
in mixed cultures and in 384-well microtitre plates [23] in the
presence of one compound from its library. The whole
system is a model of what we really are interested in: the
in vivo survival of wild-type/drug-resistant P. vivax cells
versus those of its human host. It can be seen that a set of
genetically engineered yeast strains can compute arbitrarily
complex Boolean functions of desired assay properties.4. Drug screening and repositioning
4.1. Standardized assays
We first demonstrated that we could efficiently generate stan-
dardized assays. We generated assays targeting DHFRs (wild-
type and pyrimethamine-resistant), N-myristoyltransferase(NMT) and phosphoglycerate kinase (PGK) frommultiple para-
sitic organisms: Trypanosoma brucei (African sleeping sickness),
Trypanosoma cruzi (Chagas disease), Leishmania major (Leishma-
niasis) and Schistosoma mansoni (Schistosomiasis) (electronic
supplementary material). These assays were much faster and
cheaper to develop than using standardmethods of assay devel-
opment: engineering each assay took about one person-month,
and cost approximately $15 k. A subset of these assays were
reported in [23].
4.2. Drug screening
We then tested the utility of these assays, and the efficiency of
Eve at standard screening, i.e. running in its library-screening
and hit-confirmation modes (table 1). We ran the Maybridge
Hitfinder library of approximately 14 400 chemically diverse
compounds to these assays. This identified numerous hits.
A subset of these results were reported in [23].
4.3. Drug screening for drug repositioning
We then applied the assays to the challenge of drug
repositioning—the application of knowndrugs to newdiseases
(table 1). To do this, we again used Eve in its library-screening
and hit-confirmation modes to screen and confirm hits for the
above assays, but using the Johns Hopkins University Clinical
Compound Library that contains approximately 1600 FDA-
and foreign-approved drugs. Several repositioned compounds
were found that discriminate between host and parasite, and
have passed initial cytotoxicity tests. To maximize the utility
and reuse of these screening data, they are available as open
data in Resource Description Framework (RDF) format [25]
(electronic supplementary material).
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Figure 4. The structure of TNP-470. (Online version in colour.)
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compound
The compound TNP-470 was derived from the antimicrobial
compound fumagillin (figure 4). TNP-470 is an angiogenesis
inhibitor (mediated by its irreversible binding to methionine
aminopeptidase-2 (MetAP2)) that has been investigated as an
anti-cancer drug. TNP-470 and its analogues have been
shown to bind to P. falciparum MetAP2 in vitro, to inhibit
growth of P. falciparum strains (including the chloroquine-
resistant strains W2 and C2B), and to inhibit parasitaemia
in a mouse model [26–28]. Eve’s yeast synthetic biology
assay results indicate that TNP-470 has high activity against
P. vivax DHFR (figure 5). To further confirm that DHFR is
an additional target of TNP-470 we performed DHFR
enzyme inhibition assays [29]. We observed that P. vivax
DHFR was 1000-fold more sensitive to TNP-470 than its
human counterpart; the drug’s IC50 for the parasite enzyme
being 0.16 mM, compared to more than 165 mM for human
DHFR. This is consistent with the results of Eve’s assays
and suggests that our approach identified a bona fide DHFR
inhibitor with improved selectivity.
DHFR inhibitors are currently routinely used as prophylac-
tics against malaria and are given to over a million children in
seasonal malaria chemoprevention. However, DHFR inhibi-
tors are no longer used as a standard treatment because of
the evolution of drug resistance [6]. Extensive efforts to dis-
cover a second-generation DHFR-targeted anti-malarial drug
with efficacy against pyrimethamine-resistant strains have yet
to produce a compound that has passed clinical trials [30].
Therefore, the discovery of an approved compound with
activity against DHFR is of high potential value. It is also sig-
nificant that TNP-470 is an example of ‘polypharmacology’
[31], in that it targets both Plasmodium DHFR and MetAP2.
This means that it should be pre-hardened to the evolution of
drug resistance, as this would require simultaneous alteration
of both targets.5. Automating drug development
5.1. Automating drug development
We integrated all three of Eve’s modes (library-screening, hit-
confirmation, intelligent screening) together to demonstrate
that early stage drug development can be automated, includ-
ing QSAR generate-and-test cycles. The division of labour
between Eve and the human scientists and technicians was
as follows: the problem task was first tightly defined by the
humans who engineered the assays, and defined the QSAR
problem. This was the extent of human intellectual effort.
Human manual effort was required to maintain and run Eve,
maintain consumables, yeast stocks, etc. Human manual
effort was also required to run certain programs during thedifferent stages of the cycles, as some of the steps are not
fully integrated; these program steps are predetermined, and
could if necessary be fully automated.
The first full experimental tests of the active learning loop
were conducted by splitting the screened data comprising the
heterologous DHFR yeast strains for P. falciparum, P. vivax,
and that of humans, using 4800 compounds as a training
set. The ratio of the yields of the HsDHFR and PvDHFR
and PfDHFR strains were passed to the selection algorithm,
together with fingerprints of the remaining 9600 compounds.
The results from the first ‘cherry-picking’ round (compounds
selected by active learning and using the hit-confirmation
assays) (n ¼ 96; 12 plates of eight compounds per plate;
eight replicates of six concentrations) were then added to
the original dataset, and a second cherry-picking round
conducted.We used these data to evaluate different approaches
to theproblemof combining cherry-picking andmass-screening
data. The approach based on using the mean of replicates
multiplied by log(10/conc.) was found to perform best.
We then ran the active learning loop through three iterations: an
initial set of 4800 compounds was screened (single iteration,
10 mM), and three loops of 96 cherry-picked compounds
(eight replicates, at a range of concentrations) were selected.
The mean log-weighted cherry-picking data was cycled back
into the training set.5.2. Econometric modelling
A thorough investigation of Eve’s QSAR active learning
methods, comparing intelligent screening versus standard
brute-force screening, requires the analysis of thousands of
cycles. We therefore decided to use our empirical results
from using Eve (in Library-screening mode) against the com-
plete set of 14 400 compounds of the Maybridge HitFinder
library against DHFR assays frommultiple parasitic organisms
(see above)—we considered the Johns Hopkin’s library to be
too small for intelligent screening. The idea was to use these
results as an oracle—instead of new physical experiments.
One refinement that we did not investigate was the role of
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utility of a hit
no. compounds assayed/not assayed by Eve
no. hits missed by Eve
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Figure 6. Modelling the economics of drug discovery. The econometric model of the differential utility of intelligent screening versus mass screening with
hit-confirmation.
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random order. It would have been interesting to investigate
the use molecular of diversity measures to order compounds
for screening, this would be expected to find hits faster than
random screening. In caseswhere the target has a known struc-
ture, it would have been interesting to investigate in silico
screening to order compounds as likely hits.
To quantify the utility of intelligent screening, we devel-
oped an econometric model (figure 6). In this model the net
utility is the cost saving due to not screening compounds,
minus the cost due to missing any hits, minus the cumulative
cost of the number of active learning cycles performed. Active
learning was applied to the seed input data, and predictions
made to produce simulated learning curves. The progression
of these learning curves was then compared to the base case
of standard library screening. For each 96-compound loop,
the utility equation was applied. Figure 7 shows the result
of one such run involving many cycles of learning and
demonstrates hit enrichment by intelligent screening.
We used the model to investigate a range of costings to
determine under what conditions it is economically advan-
tageous compared with performing a standard whole-library
screen. Figure 8 shows that under most conditions it is econ-
omically rational to screen intelligently. Assuming that the
probability of a compound being a hit is independent of the
size of the library, i.e. they are independent and identically dis-
tributed variables (iid), then the utility gained from intelligent
screening is proportional to the size of the library—larger
libraries produce larger savings. The iid assumption is reason-
able and, in large part, the motivation for the collation of the
very large libraries currently used for screening. However, it
is also conservative, as the difficulties in physically creating
structurally diverse libraries means that the probability of an
individual compound being a novel structural hit probably
decreaseswith the size of the library, whichmeans that the sav-
ings are probably much greater for large libraries. Therefore,
intelligent screening is more cost-effective with larger libraries,
more valuable compounds and fast cycles of assay screening
and testing—this is the standard regime for pharmaceutical
screening, suggesting that adoption of intelligent screening is
economically rational.6. Data and code
We developed a semantic data model of Eve’s-screening assay
results (see electronic supplementary material), where the root
node ‘assay triple screen’ represents the main group of data
items used to analyse the results. This root node is linked to
the node ‘Eve’ via the relation ro:has-agent. The semantics ofthis association are that Eve initiates and runs the process
‘assay triple screen’. The assay triple screen process has the fol-
lowing inputs (ro: has-input): synthetic yeast strain(s), each has a
unique identifier and ro:has-part fluorophore and DHFR target;
compound is represented by SMILES code and sio:has-identifier
compound common name and Maybridge hit finder ID; plate
is represented by a code and ro:has-partwell-column and well-
row to identify each well. The semantics of these associations
are that synthetic yeast strains, compounds and a plate partici-
pate in the assay triple screen process and are present at
the beginning of the process. The assay triple screen process
has the following outputs (ro: has-output): venus, sapphire
and cherry initial fluorescence in a well; venus, sapphire
and cherry final fluorescence in a well; venus, sapphire and
cherry doubling time in awell; venus, sapphire and cherry lag-
time2 in awell; venus, sapphire and cherry error code in awell.
The semantics of these associations are that initial and final
fluorescence, doubling time, lagtime2 and error code mea-
surements were produced by the assay process and are
present at the end of the process. Additionally, the relation
has-target-origin was introduced to link a target and an organ-
ism of origin. We included this relation and other entities that
are required to define semantic meaning of Eve data in a
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Figure 8. Summary of utility modelling. Diagram of the maximum utility of intelligent screening taken from a systematic scan of different costs/utilities in the
econometric model (a), using the screening results in (b). To make these results comprehensible, we project them down into a three-dimensional graph and
combine cost/utilities: time ratio ¼ Tc/Tm and cost ratio ¼ Uh/Cc. This indicates that intelligent screening is generally rational (there is little area of negative
utility), and that a high time-ratio (fast screening) and low cost-ratio (valuable library compounds) are most favourable.
rsif.royalsocietypublishing.org
J.R.Soc.Interface
12:20141289
8
 on July 2, 2018http://rsif.royalsocietypublishing.org/Downloaded from small ontology EVE that was specially designed to support the
semantic data model of Eve’s-screening assay results (http://
disc.brunel.ac.uk/eve.). The node ‘DHFR target’ is linked
via this relation to the host (Homo sapiens) and parasites. A
target may be drug-resistant. This is expressed via the link
sio:has-quality. The dataset is deposited at http://disc.brunel.
ac.uk/eve-dataset.
To facilitate the reuse of the code, we have placed all
the software: Eve low-level control software, QSAR software
and active learning software on GitHub using the GNU
General Public License v. 3 (https://github.com/RobotEve/
RobotEve).7. Discussion and conclusion
Eve’s standardized assays could easily be engineered for other
targets classes or target species (e.g. bacteria), for adjunctive
targets (e.g. to drug import or efflux pumps) or for combina-
tory functions (e.g. to screen for drug synergies across
multiple targets). In addition, the biological realism of the
assays could be increased by the incorporation of multiple
parasite targets within that same yeast cell, creating increas-
ingly parasite-mimetic and human-mimetic cells. The assays
could also be modified to be much faster—as using growth
as the read-out limits the speed of executing the assay.
The economics of drug development are influenced by
many factors [1–4] some technical (understanding how to
intervene to treat a disease, the difficulty of achieving the
intervention, etc.), others societal (safety standards, the
drug pricing, etc.). Although the costs of drug discovery aresubstantial, they are relatively small compared with later
stages in development. Such arguments tell against increased
automation and standardization in drug discovery making
much economic difference. However, they fail to take into
account the ‘art of the soluble’ (Sir Peter Medawar). Prevent-
ing drug failures in late-stage development is an intrinsically
very hard problem, as human biology is very complex. By
contrast, we argue that a radical decrease in the cost and
increase in the speed of drug discovery could be achieved
by the full automation and standardization of procedures.
By this, we mean a robotic system that once given a target
could autonomously develop a standardized assay for that
target, screen a compound library using that assay, confirm
hit compounds and identify lead compounds through
cycles of QSAR learning and testing. This could be achieved
today: Eve’s synthetic biology assays could be automated
using existing technology, and chemical synthesis machines
exist that could be integrated with Eve [11]. Such integration
would achieve the goal of a robotic system that could auton-
omously generate hits for targets, and radically decrease the
cost and increase the speed of drug discovery.Acknowledgements. We would like to thank Mehedi Nahian for help in
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